JP4498919B2 - 細胞の形態学的パラメーターの変化を決定する方法 - Google Patents
細胞の形態学的パラメーターの変化を決定する方法 Download PDFInfo
- Publication number
- JP4498919B2 JP4498919B2 JP2004505685A JP2004505685A JP4498919B2 JP 4498919 B2 JP4498919 B2 JP 4498919B2 JP 2004505685 A JP2004505685 A JP 2004505685A JP 2004505685 A JP2004505685 A JP 2004505685A JP 4498919 B2 JP4498919 B2 JP 4498919B2
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- light
- pattern
- wavelength
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 74
- 230000000877 morphologic effect Effects 0.000 title claims description 20
- 210000004027 cell Anatomy 0.000 claims description 182
- 239000003550 marker Substances 0.000 claims description 55
- 239000000126 substance Substances 0.000 claims description 37
- 238000009826 distribution Methods 0.000 claims description 30
- 238000012360 testing method Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 15
- 239000000463 material Substances 0.000 claims description 13
- 230000014511 neuron projection development Effects 0.000 claims description 12
- 230000008859 change Effects 0.000 claims description 11
- -1 5-carboxymethoxy-2-nitrobenzyl Chemical group 0.000 claims description 5
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 3
- 229910001923 silver oxide Inorganic materials 0.000 claims description 2
- 230000002900 effect on cell Effects 0.000 claims 2
- 238000005286 illumination Methods 0.000 description 27
- 239000003068 molecular probe Substances 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 230000009087 cell motility Effects 0.000 description 10
- 230000012292 cell migration Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 238000002372 labelling Methods 0.000 description 8
- 230000033001 locomotion Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000002502 liposome Substances 0.000 description 6
- 238000000059 patterning Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 239000005090 green fluorescent protein Substances 0.000 description 5
- 230000004660 morphological change Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 230000004941 influx Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 4
- 229910052753 mercury Inorganic materials 0.000 description 4
- 210000002241 neurite Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 108091006047 fluorescent proteins Proteins 0.000 description 3
- 102000034287 fluorescent proteins Human genes 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102220566468 GDNF family receptor alpha-1_S65G_mutation Human genes 0.000 description 2
- 102220566479 GDNF family receptor alpha-1_S72A_mutation Human genes 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000005283 ground state Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000001678 irradiating effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000008384 membrane barrier Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000006303 photolysis reaction Methods 0.000 description 2
- 230000015843 photosynthesis, light reaction Effects 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- UIBRZOTWRMHYFJ-UHFFFAOYSA-N 1,2-dihydroazulene Chemical class C1=CC=C[C]2[CH]CCC2=C1 UIBRZOTWRMHYFJ-UHFFFAOYSA-N 0.000 description 1
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 1
- 241000243290 Aequorea Species 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000028600 axonogenesis Effects 0.000 description 1
- 210000002457 barrier cell Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000298 carbocyanine Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000004662 cellular morphological change Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000009614 chemical analysis method Methods 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000695 excitation spectrum Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003703 image analysis method Methods 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- AHEWZZJEDQVLOP-UHFFFAOYSA-N monobromobimane Chemical compound BrCC1=C(C)C(=O)N2N1C(C)=C(C)C2=O AHEWZZJEDQVLOP-UHFFFAOYSA-N 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000007856 photoaffinity label Substances 0.000 description 1
- QWYZFXLSWMXLDM-UHFFFAOYSA-M pinacyanol iodide Chemical compound [I-].C1=CC2=CC=CC=C2N(CC)C1=CC=CC1=CC=C(C=CC=C2)C2=[N+]1CC QWYZFXLSWMXLDM-UHFFFAOYSA-M 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000009494 specialized coating Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5026—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on cell morphology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Description
a)第一の波長の光にマーカーを露光することによって実質的に検出不能な状態から検出可能な状態へ変換することができるマーカー物質で標識された細胞集団中の細胞の亜集団を第一の波長の光に露光する工程と、
b)細胞集団の少なくとも一部を第二の波長の光に最初に露光してマーカー物質の分布の第一のパターンを検出する工程と、
c)細胞集団の一部を第二の波長の光に二度目に露光してマーカー物質の分布の第二のパターンを検出する工程と
を含み、マーカー物質の分布の第一のパターンと第二のパターンの差異が細胞の形態学的パラメーターの変化の指標である、方法を提供する。
i)全ての細胞が第二の波長の光に露光され、マーカー物質の分布のパターンが、細胞全部にまたがって記録される細胞集団全体であって、このような検査は第一の波長の光を用いた照明を達成するように用いられる光パターン化の手段を排除することによって達成される、細胞集団全体であっても;又は
ii)第一の波長の光に露光される細胞の同じ亜集団が第二の波長の光に露光され、マーカー物質の分布のパターンが記録される細胞の亜集団であって、このような検査は第一の波長の光を用いた照明を達成するように用いられる光パターン化の手段の空間的な位置を保持すること、及び第二の波長の光を用いて照明を達成するためにこの手段を用いることによって達成される、細胞の亜集団であっても;又は
iii)第一の波長の光に露光される細胞の異なる亜集団が第二の波長の光に露光され、マーカー物質の分布のパターンが記録される細胞の亜集団であって、このような検査は第一の波長の光を用いた照明を達成するように用いられる光パターン化の手段の空間的な位置を変更すること、及び第二の波長の光を用いて照明を達成するためにこの手段を用いることによって達成される、細胞の亜集団であってもよい。
i)例えば、培養中の細胞が増殖及び分裂する場合、細胞がサイズ、形状又は位置の変化を示すが、この細胞の少なくとも一部が同じ空間を占める、一過性の形態学的変化;
ii)細胞全体が以前に占められた位置と重複しない空間を占めるように細胞位置が変化する、無作為の様式での細胞の移動(細胞運動性)、又は化学的もしくは物理的刺激に向かうかもしくはそれから離れる細胞の移動(細胞遊走)に関与する細胞位置の変化;並びに
iii)細胞サイズ及び形状の永続的な形態学的変化であって、代表的には細胞分化の結果として生じ、細胞の量及び面積の有意な増大を生じ得る、形態学的変化、
として分類することができる。
a)それらは、水性培地及び緩衝液中に自由に溶解可能でなければならない;
b)それらは、細胞膜を横切って又は細胞膜内に自由に浸透可能でなければならないが、細胞の内側に又は細胞と会合して残留しなければならない;
c)それらは、活性化に適切な波長の光の非存在下では、自由溶液内及び細胞内で、検出不能であるか又は実質的に検出不能でなければならない、
として記載されるような、多数の所望される特性を有する
本発明による使用のための特に好ましいマーカー物質は、
a)活性化に適切な波長の光に対する露光の後には、自由溶液内で、検出不能であるか又は実質的に検出不能;
b)活性化に適切な波長の光に対する露光の後には、細胞の内側で検出可能、
という多数のさらなる特性を有する。
Claims (10)
- 細胞の形態学的パラメーターの変化を測定する方法であって、
a)第一の波長の光にマーカーを露光することによって実質的に検出不能な状態から検出可能な状態へ変換することができるマーカー物質で標識された細胞集団中の細胞の亜集団を第一の波長の光に露光する工程と、
b)細胞集団の少なくとも一部を第二の波長の光に最初に露光してマーカー物質の分布の第一のパターンを検出する工程と、
c)細胞集団の一部を第二の波長の光に二度目に露光してマーカー物質の分布の第二のパターンを検出する工程と
を含み、マーカー物質の分布の第一のパターンと第二のパターンの差異が細胞の形態学的パラメーターの変化の指標である、方法 - 細胞サイズ、細胞位置及び/又は細胞形状を前記形態学的パラメーターとして選択する、請求項1記載の方法。
- 細胞形状の変化が神経突起成長の指標である、請求項2記載の方法。
- 以下の工程c):細胞集団の一部をさらにN回(Nは1以上)第二の波長の光に露光し、マーカー物質の分布のパターンを検出し、マーカー物質の分布のパターンを細胞の形態学的パラメーターの変化の指標となるプロフィールの作製に用いる工程をさらに含む、請求項1乃至請求項3記載の方法。
- 細胞の形態学的パラメーターに対する効果を決定すべき試験薬をスクリーニングする方法であって、
(a)試験薬の存在下及び非存在下で、請求項1乃至請求項4のいずれか1項記載の方法を実施する工程と、
(b)試験薬の有無によるマーカー物質の分布のパターンの差異を測定する工程と、
を含み、
試験薬の有無による分布のパターンの差異が細胞の形態学的パラメーターに対する試験薬の効果の指標である、方法。 - 細胞の形態学的パラメーターに対する効果を決定すべき試験薬をスクリーニングする方法であって、
(a)試験薬の存在下で、請求項1乃至請求項4のいずれか1項記載の方法を実施する工程と、
(b)マーカー物質の分布のパターンと試験薬の非存在下で測定した分布の対照パターンとを比較する工程と
を含む方法。 - マーカーがケージド蛍光分子及びフォトクロミック化合物から選択される、請求項1乃至請求項6のいずれか1項記載の方法。
- ケージド蛍光分子が、N−(DMNB−ケージドフルオレセイン)−1,2−ジヘキサデカノイル−sn−グリセロ−3−ホスホエタノールアミン及び5−カルボキシフルオレセイン−bis−(5−カルボキシメトキシ−2−ニトロベンジル)エーテル−アラニン−カルボキサミド、スクシンイミジルエステルから選択される、請求項7記載の方法。
- フォトクロミック物質が、酸化銀ナノクラスター粒子、スピロベンゾピラン及びナフタセネキノンから選択される、請求項7記載の方法。
- 請求項1乃至請求項5のいずれか1項記載の細胞の形態学的パラメーターの変化を測定する方法における、ケージド蛍光分子及びフォトクロミック化合物から選択されるマーカー物質の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0211072.4A GB0211072D0 (en) | 2002-05-15 | 2002-05-15 | Reagent and method for the determination of changes in a cellular morphological parameter |
PCT/GB2003/001904 WO2003098210A1 (en) | 2002-05-15 | 2003-05-07 | Method for the determination of changes in a cellular morphological parameter |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005525127A JP2005525127A (ja) | 2005-08-25 |
JP4498919B2 true JP4498919B2 (ja) | 2010-07-07 |
Family
ID=9936674
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004505685A Expired - Fee Related JP4498919B2 (ja) | 2002-05-15 | 2003-05-07 | 細胞の形態学的パラメーターの変化を決定する方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US7527940B2 (ja) |
EP (1) | EP1504259B1 (ja) |
JP (1) | JP4498919B2 (ja) |
KR (1) | KR20050007539A (ja) |
CN (1) | CN100507562C (ja) |
AT (1) | ATE307335T1 (ja) |
AU (1) | AU2003223001B2 (ja) |
CA (1) | CA2485659C (ja) |
DE (1) | DE60301959T2 (ja) |
DK (1) | DK1504259T3 (ja) |
ES (1) | ES2250885T3 (ja) |
GB (1) | GB0211072D0 (ja) |
IL (1) | IL164843A0 (ja) |
WO (1) | WO2003098210A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080279441A1 (en) * | 2005-03-29 | 2008-11-13 | Yuichiro Matsuo | Cell-Image Analysis Method, Cell-Image Analysis Program, Cell-Image Analysis Apparatus, Screening Method, and Screening Apparatus |
RU2305270C2 (ru) * | 2005-05-18 | 2007-08-27 | Андрей Алексеевич Климов | Способ флуоресцентной наноскопии (варианты) |
US8357917B2 (en) * | 2005-09-10 | 2013-01-22 | Baer Stephen C | High resolution microscopy using an optically switchable fluorophore |
CN101226190B (zh) * | 2007-01-17 | 2013-07-03 | 深圳迈瑞生物医疗电子股份有限公司 | 流式细胞术的自动分类方法和装置 |
JP2010207133A (ja) * | 2009-03-10 | 2010-09-24 | Sony Corp | 細胞分離方法 |
CA2776501C (en) * | 2009-10-02 | 2022-04-19 | Blanchette Rockefeller Neurosciences Institute | Fibroblast growth patterns for diagnosis of alzheimer's disease |
US9134301B2 (en) * | 2010-11-22 | 2015-09-15 | Bio-Rad Laboratories, Inc. | Sorting of adherent cells by selective transformation of labels |
WO2018012601A1 (ja) * | 2016-07-14 | 2018-01-18 | 大日本印刷株式会社 | 画像解析システム、培養管理システム、画像解析方法、培養管理方法、細胞群製造方法及びプログラム |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5635608A (en) * | 1994-11-08 | 1997-06-03 | Molecular Probes, Inc. | α-carboxy caged compounds |
US5989835A (en) * | 1997-02-27 | 1999-11-23 | Cellomics, Inc. | System for cell-based screening |
US5885840A (en) * | 1997-02-10 | 1999-03-23 | Compucyte Corp. | Multiple assays of cell specimens |
US6416959B1 (en) * | 1997-02-27 | 2002-07-09 | Kenneth Giuliano | System for cell-based screening |
KR100618502B1 (ko) * | 1998-03-16 | 2006-09-01 | 지이 헬스케어 바이오-사이언시즈 코프. | 공초점 마이크로스코피 영상 시스템에서 사용하기 위한 전자기 방출의 집속 시스템 및 방법 |
EP1203214B1 (en) * | 1999-08-05 | 2005-11-09 | Cellomics, Inc. | Optical system analysis of cells |
US6986993B1 (en) * | 1999-08-05 | 2006-01-17 | Cellomics, Inc. | System for cell-based screening |
CA2353120A1 (en) * | 2001-07-16 | 2003-01-16 | Cardiogenics Inc. | Caged compound cleaving process |
US6933154B2 (en) * | 2002-07-09 | 2005-08-23 | Medispectra, Inc. | Optimal windows for obtaining optical data for characterization of tissue samples |
-
2002
- 2002-05-15 GB GBGB0211072.4A patent/GB0211072D0/en not_active Ceased
-
2003
- 2003-05-07 WO PCT/GB2003/001904 patent/WO2003098210A1/en active IP Right Grant
- 2003-05-07 EP EP03718967A patent/EP1504259B1/en not_active Expired - Lifetime
- 2003-05-07 US US10/514,924 patent/US7527940B2/en not_active Expired - Fee Related
- 2003-05-07 DK DK03718967T patent/DK1504259T3/da active
- 2003-05-07 AT AT03718967T patent/ATE307335T1/de not_active IP Right Cessation
- 2003-05-07 JP JP2004505685A patent/JP4498919B2/ja not_active Expired - Fee Related
- 2003-05-07 KR KR10-2004-7018283A patent/KR20050007539A/ko not_active Application Discontinuation
- 2003-05-07 DE DE60301959T patent/DE60301959T2/de not_active Expired - Lifetime
- 2003-05-07 CN CNB038107260A patent/CN100507562C/zh not_active Expired - Fee Related
- 2003-05-07 CA CA2485659A patent/CA2485659C/en not_active Expired - Fee Related
- 2003-05-07 ES ES03718967T patent/ES2250885T3/es not_active Expired - Lifetime
- 2003-05-07 AU AU2003223001A patent/AU2003223001B2/en not_active Ceased
-
2004
- 2004-10-26 IL IL16484304A patent/IL164843A0/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003223001B2 (en) | 2006-08-10 |
KR20050007539A (ko) | 2005-01-19 |
DE60301959D1 (de) | 2006-03-02 |
GB0211072D0 (en) | 2002-06-26 |
US20050227310A1 (en) | 2005-10-13 |
WO2003098210A1 (en) | 2003-11-27 |
CN1653331A (zh) | 2005-08-10 |
DE60301959T2 (de) | 2006-07-27 |
EP1504259A1 (en) | 2005-02-09 |
CN100507562C (zh) | 2009-07-01 |
ATE307335T1 (de) | 2005-11-15 |
CA2485659C (en) | 2011-04-19 |
ES2250885T3 (es) | 2006-04-16 |
US7527940B2 (en) | 2009-05-05 |
IL164843A0 (en) | 2005-12-18 |
DK1504259T3 (da) | 2006-03-06 |
CA2485659A1 (en) | 2003-11-27 |
EP1504259B1 (en) | 2005-10-19 |
JP2005525127A (ja) | 2005-08-25 |
AU2003223001A1 (en) | 2003-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sauer et al. | Single-molecule localization microscopy in eukaryotes | |
Panchuk-Voloshina et al. | Alexa dyes, a series of new fluorescent dyes that yield exceptionally bright, photostable conjugates | |
St-Pierre et al. | High-fidelity optical reporting of neuronal electrical activity with an ultrafast fluorescent voltage sensor | |
Thompson et al. | Recent advances in fluorescence correlation spectroscopy | |
Takahashi et al. | Watching neuronal circuit dynamics through functional multineuron calcium imaging (fMCI) | |
EP3252452A1 (en) | Method for imaging and analysis of a biological specimen | |
Mason et al. | Novel fluorescence-based approaches for the study of biogenic amine transporter localization, activity, and regulation | |
CN108139408A (zh) | 蛋白质保持扩展显微法 | |
EP1248108B1 (en) | method of cellular screening and substrates suitable for it | |
JP4498919B2 (ja) | 細胞の形態学的パラメーターの変化を決定する方法 | |
Maity et al. | Label-free imaging of neurotransmitters in live brain tissue by multi-photon ultraviolet microscopy | |
Gonzalez et al. | Voltage imaging with a NIR-absorbing phosphine oxide rhodamine voltage reporter | |
DE4301005A1 (de) | Verfahren und Vorrichtung zur Bewertung der Fitness von Biopolymeren | |
DE10138072A1 (de) | Verfahren und Vorrichtung zum Bestimmen von Proteinen auf einem Reaktionsträger | |
Lala | Fluorescent and photoactivable probes in depth-dependent analysis of membranes | |
Lombardi et al. | Visualizing GABA A receptor trafficking dynamics with fluorogenic protein labeling | |
Jaiswal et al. | Optical monitoring of single cells using quantum dots | |
Le Marchand et al. | New imaging tools to study synaptogenesis | |
US20050147989A1 (en) | Screening assay for aggregations | |
DE10058596A1 (de) | Verfahren zum Screening von chemischen Verbindungen zur Modulierung der Wechselwirkung einer EVH1-Domäne oder eines Proteins mit einer EVH1-Domäne mit einer EVH1-Bindedomäne oder einem Protein mit einer EVH1-Bindedomäne sowie ein Verfahren zum Nachweis besagter Wechselwirkung | |
Chu et al. | Multiplexed single-molecule fluorescence measurements enabled by multi-parameter spectroscopic detection of nanostructured FRET labels | |
Bhupathi et al. | Single Molecule Imaging Using State-of-the-Art Microscopy Techniques | |
Patra | Application and new developments in fluorescence spectroscopic techniques in studying individual molecules | |
US20150004636A1 (en) | Neuronal biosensor for detection of toxins | |
Mizuguchi et al. | Multimodal Nonlinear Optical Imaging of Plasma Membrane by Dye-Based Sum-Frequency Generation using a Coherent Anti-Stokes Raman Scattering Microscope |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060426 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060426 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090501 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090501 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20090501 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090513 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090603 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090610 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090703 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090716 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100316 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100414 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130423 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |